1. John E. Bennett. Antifungal agents. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York Mc Graw Hill Medical 2011. Page – 1586-1588.
2. Bausch Health Americas, Inc. Maximal Use of Luliconazole Cream 1% in Pediatric Participants with Moderate to Severe Tinea Pedis or Tinea Cruris. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on November 2019] [Accessed 30th October 2020] https://clinicaltrials.gov/ct2/show/NCT02767271
3. Deepshikha Khanna and Subhash Bharti. Luliconazole for the treatment of fungal infections: an evidence-based review. NCBI; PMC US National Library of Medicine, National Institute of Health. September 2014. [Accessed 30th October 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181444/
4. Aditya K Gupta and Deanne Daigle. A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections. NCBI; PMC US National Library of Medicine, National Institute of Health. January 2016. [Accessed 30th October 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723097/
5. Valeant Pharmaceuticals. U.S. Food & Drug Administration. [Revised on November 2013] [Accessed 30th October 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204153s000lbl.pdf